NCT07426211 Impact of Shift Work on Glucose and Lipid Metabolism of Hospital Workers
| NCT ID | NCT07426211 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Olga Ramich (formerly Pivovarova) |
| Condition | Chronodisruption |
| Study Type | OBSERVATIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 48 participants in total. It began in 2026-06-01 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to evaluate circadian glucose, activity and dietary rhythms, as well as metabolic and cardiovascular risk associated with night shift work, sleep quality and well-being in a cohort of hospital staff, comparing employees with night shifts to employees without night shifts.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 67 * Male or female * Currently employed * Body-Mass-Index (BMI) \<40 kg/m2 * Working hours ≥28 hours/week * Employees working night shifts (group A): (1) Working night shifts for \>1 year, (2) at least two night shifts within the 2-week observation period * Employees not working night shifts (group B): No night shifts for \>1 year * Capable of giving consent * Health insurance * Good knowledge of German Exclusion Criteria: * Pregnancy and breastfeeding * Special diets, e.g. intermittent fasting * Severe acute or chronic diagnosed conditions, e.g., diabetes mellitus, liver or kidney disease (e.g., cirrhosis of the liver or kidney disease with a GFR \< 60), heart attack within the last 6 months, stroke, or systemic infections; current cancer or cancer diagnosed within the last 2 years * Bariatric surgery * Hereditary or acquired blood clotting disorders * severe mental health conditions, e.g., substance use disorders, eating disorders, or uncontrolled depression (individual assessment by study staff, if necessary following consultation with a physician) * Holiday in a different time zone (≥ 2 hours time difference) one month before study participation or within the 2-week observation phase * Participation in another study that could influence the results of the current study * Specific drug therapies that could influence the study results, e.g., antidiabetic medications including GLP-1 analogs, melatonin (Individual assessment by study staff, if necessary after consultation with a physician) * Implanted electronic medical devices, e.g., pacemakers or neurostimulators (to be assessed on a case-by-case basis by study staff, following consultation with a physician if necessary) * Physical or mental difficulties in understanding and following instructions from study staff
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07426211 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 67 Years, studying Chronodisruption. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07426211 currently recruiting?
Yes, NCT07426211 is actively recruiting participants. Contact the research team at olga.ramich@dife.de for enrollment information.
Where is the NCT07426211 trial being conducted?
This trial is being conducted at Berlin, Germany, Berlin, Germany.
Who is sponsoring the NCT07426211 clinical trial?
NCT07426211 is sponsored by Olga Ramich (formerly Pivovarova). The trial plans to enroll 48 participants.